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ABSTRACT 
The aim of this pilot study was to determine if there was a relationship between 
disease severity, measured by right ventricular systolic pressure (RVSP), and 
gas exchange, measured by oxygen consumption, during the six-minute walk 
test (6MWT) in ten patients with idiopathic PAH. In addition, we sought to 
determine if there was a relationship between the change in RVSP and the 
change in gas exchange following several months of therapy with the goal of 
reducing RVSP. The optimal treatment (medication) was determined by the 
subjects’ doctors and was not recorded for this study. For test 1, we found a 
negative non-significant relationship between end-tidal carbon dioxide (PETCO2) 
and RVSP (r=-0.6, p=0.094) and a negative non-significant correlation between 
PETCO2 and RVSP (r=-0.7, p=0.13) for test 2. We also found a positive, non-
significant correlation between minute ventilation (VE) relative to carbon dioxide 
production (VE/VCO2) assessed at the mouth and RVSP (r=0.6, p=0.06) for test 1 
and a positive non-significant correlation between VE/VCO2 and RVSP (r=0.5, 
p=0.33) for test 2. We found a significant drop in RVSP (p=0.049), PETCO2 
(p=0.023) and VE/VCO2 (p=0.025) between test 1 and test 2.  We found no 
relationship between the change in RVSP and the change in PETCO2; we found a 
moderate, non-significant, relationship between change in RVSP and change in 
VE/VCO2 (r= 0.7, p=0.09). Due to the small sample size there was no significant 
relationship between the change in RVSP and the change in VE/VCO2; however, 
the trend towards significance suggests that the assessment of the gas 
exchange parameter VE/VCO2 may be sensitive enough to determine changes in 
disease severity in patients with pulmonary hypertension in a study with a larger 
sample size. In support of this, we performed a post-hoc power analysis and 
determined that a study with a sample size of 16 would be sufficient to determine 
changes in RVSP and changes in VE/VCO2. Future studies should look at the 
relationship between the change of RVSP and the change of VE/VCO2 with a 
larger sample size under standard conditions in regards to treatment and timing 
between the tests. 
  iii 
  
 
Key Words: Pulmonary arterial hypertension, six-minute walk test, 
echocardiogram
  iv 
TABLE OF CONTENTS 
Acknowledgements………………………………..……………………………………. i 
Abstract……………………………………………….………………………................ ii 
Table of Contents…………………………………………………………….………… iii 
List of Tables……………………………………………………...……………………. iv 
List of Figures…………………………………………………..………………………. v 
Chapter 1. Introduction……………………………………………….…….………….. 2 
Chapter 2. Review of Literature……………………………………..………………... 6 
Pulmonary arterial hypertension….………………….……………………….. 7 
Six-minute walk test……………………………..……….……….................... 8 
Echocardiogram…………………………………………………………..……10 
Chapter 3. Methodology……………………………………………………………… 12 
           Experimental design...………………………………………………………... 13 
 Experiment subjects...………………………………………………………... 14 
 Tests…………………………...……………………………………………..... 14 
 Statistical Analysis…………………………………………………………….. 16 
Chapter 4. Results…………………………………………………………………….. 18 
Chapter 5. Discussion……………..………………………………………................ 22 
Chapter 6. Conclusion…………………………………………..…………….……… 26 
References…………………………………………………………………………….. 28 
Appendix……………………………………………………………………………….. 38 
  
  v 
 
LIST OF TABLES 
 
Table 1: Functional classification of disease severity of PAH patients ………….39 
Table 2: Comparison of VE/VCO2 and PETCO2 in healthy and PAH subjects......40 
Table 3: Borg Scale………………..…………………………………………………. 41 
Table 4: Demographics of subjects…………………………………………………. 42 
Table 5: Six-minute walk test physiology data ………………………………….....43 
Table 6: Differences of gas exchange and RVSP for test 1 and 2…………….…44 
Table 7: Correlations of PETCO2, VE/VCO2, RVSP between test 1 and 2….........45 
Table 8: Change between PETCO2, VE/VCO2 and RVSP for test 1 and 2…….…46 
 
 
 
 
 
  vi 
LIST OF FIGURES 
Figure 1: Correlation between RVSP and VE/VCO2 for test 1 (r=0.6, p=0.06)…47 
Figure 2: Correlation between RVSP and VE/VCO2 for test 2 (r=0.5, p=0.33)…48 
 
Figure 3: Correlation between RVSP and PETCO2 for test 1 (r=0.6, p=0.06)….49 
 
Figure 4: Correlation between RVSP and PETCO2 for test 2 (r=0.7, p=0.13)….50 
 
 
 
   2 
 
 
 
 
 
 
 
 
CHAPTER 1. INTRODUCTION 
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Pulmonary Arterial Hypertension (PAH) is an uncommon disease that affects the 
blood flow through the lungs. There are 7.1 PAH cases per million of which 46% 
are diagnosed with idiopathic PAH (Peacock, 2007). Although the disease is 
rare, PAH has increasingly become a focus of research studies given the poor 
prognostic outcomes in patients with PAH and the fact that early diagnosis can 
result in a marked improvement in quality of life. PAH can affect any gender, 
ethnicity, and age, although it is more commonly reported in adulthood (Lung 
Foundation, 2011). Chronic obstruction of the blood vessels in the lungs raises 
the blood pressure of the pulmonary arteries over time, which results in an 
increased workload for the heart.  
The Lung Foundation lists several types and causes of PAH (Lung Foundation, 
2011) which include: 
 Primary pulmonary hypertension (familial and idiopathic) 
 Scleroderma (also known as systemic sclerosis) 
 Lupus 
 HIV/AIDS 
 Congenital heart defects 
 Some liver disorders 
 Certain drugs or toxins 
Depending on the severity of the disease the impact of PAH on daily life can 
range from little (Class I) where the patient has no limitation in daily or physical 
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activity to severe (Class IV) where the patient encounters breathlessness, fatigue 
and dizziness at a rested state (Table 1). 
 
Because the symptoms of PAH can be mistaken for other diseases, several tests 
are required to diagnose the patient with PAH. The Lung Foundation suggests 
echocardiograms, breathing and walking tests, computed tomography (CT) 
scans and a right heart catheterization to correctly diagnose PAH (Lung 
Foundation, 2011). The gold standard for the assessment of pulmonary artery 
pressure is right heart catheterization, but this procedure is invasive, expensive 
and requires a highly-specialized team to perform the procedure. The disease 
severity of PAH is best diagnosed non-invasively through assessment of RVSP 
via echocardiogram since the main cause of PAH is obstruction of the pulmonary 
blood vessels which can be assessed as a back-pressure on the right side of the 
heart. (Howard, 2011; Pietra, 1989) However, echocardiography remains 
somewhat expensive, requires the skills of an ultrasound technician, and may 
require the use of a contrast agent to assess RVSP due to low signal strength of 
the variable used to assess RVSP, tricuspid regurgitant velocity (TRV). Based on 
the limitations of right heart catheterization and echocardiography, a non-invasive 
test for PAH is needed. The six minute walk test (6MWT) would be a less 
expensive and easier tool to assess disease status.  
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The 6MWT is a well-established test for pulmonary function, especially in 
patients with cardiopulmonary disease, as it does not require a maximal effort 
(Rasekaba and Lee et al. 2009; Paciocco, 2001). However, there is some 
evidence to suggest that the 6MWT is not sensitive to disease severity, 
particularly in younger individuals more likely to reach a 6MWT ceiling (Rasekaba 
and Lee et al., 2009). Recent evidence suggests that the gas exchange 
measurements made during exercise in PAH patients are unique to PAH and 
may reflect disease severity (Hansen, 2007). For this pilot study, a repeated 
measures study design was utilized in which we sought to examine the 
relationship between gas exchange measurements made during the 6MWT and 
disease severity in patients with PAH and to determine if gas exchange 
measurements during 6MWT were sensitive enough to determine changes in 
disease severity.  
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CHAPTER 2. REVIEW OF LITERATURE 
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Pulmonary arterial hypertension 
PAH is defined as a sustained elevation of pulmonary arterial pressure of >25 
mmHg at rest and >30 mmHg with exercise (Table 2) (Tolle, 2008). Pathogenic 
factors resulting in  PAH include scarring of connective tissue (fibrosis), blood 
clot (thrombosis), enlargement of the walls (myocardial ventricular hypertrophy), 
and constriction of the pulmonary arterial blood vessels (vasoconstriction) (Smith, 
2013) which result in a decreased intraluminal diameter and an increased 
pulmonary vascular resistance (Smith, 2013). The increase in vascular 
resistance raises the pulmonary arterial pressure resulting in PAH (Gaine, 1998). 
The remodeling of the pulmonary arterial walls due to sclerosis and fibrosis 
impairs the oxygen diffusion from the lungs into the blood stream (Smith, 2013) 
and from carbon dioxide (CO2) from the blood out of the lungs. This ventilation-
perfusion mismatch results in an increased dead space, a decreased partial 
pressure of end-tidal carbon dioxide (PETCO2), and an increased ventilatory 
requirement (Sun, 2001). In PAH patients, PETCO2 is even further attenuated with 
exercise (Riley, 2000). The increased ventilation requirement is shown as an 
elevated ventilatory equivalent ratio for CO2 (VE/VCO2) ratio. From a disease 
standpoint PETCO2 is lower in patients with pulmonary hypertension, because 
there is an inability for CO2 to diffuse from the blood through the lungs 
(Yasunobu, 2005; Hansen, 2014).  Lower PETCO2 and higher VE/VCO2 are 
indicative of more severe pulmonary hypertension. VE/VCO2 in resting and 
exercising states falls below 30 in healthy subjects (Arena, 2009) indicating that 
   8 
the CO2 production and VE increase at the same rate. However, in PAH patients, 
the ratio is between 30 to 60 due to increased ventilation with decreased 
exhalation of CO2. PETCO2 in healthy subjects ranges between high 30s to low 
40s mmHg at rest with an increase of 3 - 8 mmHg during exercise (Arena, 2009). 
In PAH patients resting values of PETCO2 fall between low 20s to low 30s mmHg 
and during exercise ranges from low 30s down to 18 mmHg (Table 2). With 
increased disease severity the change of resting to exercising PETCO2 decreases 
whereas in healthy subjects it increases (Arena, 2009). Historically, the function 
of the right ventricle is essential to determine the severity and disease status of 
the pulmonary disease (Voelkel, 2006). The RVSP is typically evaluated using 
invasive (right heart catheterization) or expensive (such echocardiography or 
magnetic resonance imaging) techniques. Several non-invasive tests have been 
used to evaluate the severity of PAH; the most accessible is the well-established 
6MWT. This test has sound clinical guidelines (ARHP Research Committee, 
2011), requires little equipment, and is self-regulating by the patient and, as 
such, does not require high-intensity efforts which could be potentially harmful.  
 
Functional testing of PAH 
 Six-minute walk test 
The 6MWT is a test designed for patients with heart failure or chronic respiratory 
diseases to measure functional exercise capacity (ARHP Research Committee, 
2011). The purpose of the test is to cover as much distance as possible in six 
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minutes. The walking course is 30 meters and is marked by cones or tape which 
the subject walks between. Exercise testing like the 6MWT provides a valid 
assessment of heart function since distance covered is correlated to the oxygen 
uptake (VO2) (Deboeck and Niset et al., 2005; ARHP Research Committee, 
2011) and there is a direct relationship between maximal cardiac output and 
oxygen delivery and consumption (Howard, 2011). Thus, the 6MWT is a safe, 
easy, and non-invasive measurement of functional capacity. One previous study 
(Deboeck and Niset et al., 2005) compared the maximal oxygen uptake 
(VO2max) of PAH patients of the 6MWT with the gas exchange parameters 
during a cardiopulmonary bicycle exercise test. In this study the VO2max for the 
6MWT was higher than the bicycle test. Deboaek suggested that one of the 
reasons could be that PAH patients do not have the required lower body muscle 
mass to achieve maximum cardiac output so whole-body exercise may be more 
accurate. The protocol of the 6MWT matches with the typical exercise pattern for 
PAH patients and is therefore a more accurate tool for PAH patients to obtain 
VO2max than the bicycle exercise test. Even the simple assessment of distance 
walked during a 6MWT could be a powerful tool for patients with PAH in hospitals 
and centers that lack a portable VO2 testing device. A comparison study by 
Oudiz and Barst et al. (2006) showed a high correlation between VO2 and 
walking distance if the test is conducted by trained staff and the results are 
weight-adjusted (Oudiz , 2006). Since the walk test can vary due to perceptional 
variations, Redelmaier et al. suggests a distance difference of 54 meters 
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between tests to be clinical significant (Redelmeier and Bayoumi et al., 1997). 
The average distance for the 6MWT in PAH patients is 297 m (Rasekaba and 
Lee et al., 2009). Although the distance walked is important, it is likely that the 
assessment of gas exchange parameters gives the clinician more information 
regarding disease severity. In addition to measures of gas exchange, the 
assessment of oxygen saturation (O2 Sat) during exercise is important in patients 
with PAH. O2 Sat is a relative measure of the amount of oxygen that the blood can 
carry expressed as a percent of hemoglobin saturated with oxygen. Patients with 
more severe pulmonary hypertension can demonstrate drops in arterial O2 Sat 
due to ventilation-perfusion mismatching. A study by Paciocco et al. researched 
the relationship between distance walked of the 6MWT and oxygen desaturation 
and found that a change of O2 Sat between rest time and peak time of >10% 
increased mortality by 2.9 years (Paciocco, 2001). 
 
Echocardiogram 
The echocardiogram uses ultrasound waves to assess the structure and function 
of the heart. Since PAH is defined as an elevated pulmonary arterial pressure 
(PAP), the echocardiogram is a useful but rather expensive tool to diagnose PAH 
(Mathai, 2008). The echocardiogram allows measuring the RSVP through the 
assessment of TRV which assesses back pressure from the lungs. The TRV is 
derived through the Doppler evaluation and the PAP is calculated 4*TRV2 + 5 
mmHg (Chan, 1987), where 5 mmHg is an estimate of right atrial pressure. 
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RSVP in healthy subjects is below 25 mmHg; however, due to increased arterial 
stenosis, RSVP in PAH patients increases to over 25 mmHg.  
 
The purpose of this pilot study was to determine if there was a relationship 
between RVSP (measured by an echocardiogram) and gas exchange (measured 
during a 6MWT). We focused on RVSP, PETCO2 and VE/VCO2 as these are 
indicators for disease severity.  
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CHAPTER 3. METHODOLOGY 
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Experimental Design 
 
To determine the relationship between gas exchange and RVSP in 
patients with PAH, we assessed both variables before (test 1) and following (test 
2) treatment guided to reduce RVSP. First, we looked at the relationship between 
our three main variables (RVSP, PETCO2, VE/VCO2) within each test. Then we 
compared the change between test 1 and test 2 within each variable. Finally, we 
correlated the change between test 1 and test 2 of the gas exchange variables to 
the change between test 1 and test 2 to RVSP. If there is a relationship between 
the changes of disease severity and the changes of gas exchange, the 6MWT 
can become a more-widely used tool, possibly in place of the more expensive 
echocardiogram as a measurement of the change in disease status following 
treatment in patients with PAH in order to further guide therapy. 
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Experimental subjects 
 
Ten subjects identified with idiopathic PAH were recruited for this study 
from the Prince Charles hospital (Brisbane, Australia). All subjects were patients 
at Prince Charles hospital, had idiopathic PAH, and gave written consent for 
participation of this study. Subjects were excluded from the study if they were not 
able to walk, claustrophobic, or on a permanent oxygen delivery device. To 
compare the PAH values to a healthy range we used the values indicated by a 
pulmonary hypertension review by Arena (2009). The subject was informed 
about the test and signed the consent form for the study. The subjects were 
recruited due to the idiopathic nature of their disease. The two tests were part of 
the standard testing for the subjects and were separated by several months of 
treatment with the goal of reducing RVSP. Treatments were not recorded and 
thus were not part of the analysis of this study. Since the purpose of this pilot 
study was to determine if there is a relationship between two assessment tools 
for the severity of PAH, it did not include any other variables but two tests with 
their respective measurements of RVSP, PETCO2 and VE/VCO2.  
 
Six-minute walk test 
 Every subject performed two tests (6MWT and echocardiogram as 
described below) on two different days that were separated by at least one 
month. These tests were part of the regular check-up routine. The average time 
between the 6MWTs was one year and four months. Both testing days were 
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identical, other than the subjects were treated with the goal of reducing RVSP 
prior to the post-therapy test (test 2). To determine gas exchange, the trained 
medical staff placed a face mask over the mouth of the sitting subject and put the 
portable metabolic analyzer, which was calibrated before each test (Cortex, 
MetaMax, Koln, Germany). The portable metabolic analyzer fitted like a vest 
around the subject and was loosely tightened to ensure it would not fall off while 
walking. To measure O2 Sat, two electrodes of the pulse oximeter were placed 
above each eye brow and secured with a headband. The pulse oximeter device 
(Nonin Medical, Inc., Plymouth, Minnesota, MN, USA) was held by the 
physiotherapist during the test. A heart rate strap (Polar, Kempele, Finland) was 
tightened below the chest of the subject. The staff instructed the subject about 
the Borg scale (Table 3), which was used during the 6MWT. The Borg scale is a 
scale that ranges from 6 to 20 with 6 being resting with no physical exertion and 
20 being maximal exercise. When the subject was ready, the physiotherapist and 
the subject advanced to the start line of the walk test. Once the subject was 
ready, the physiotherapist started the clock and the subject walked as fast as his 
or her ability allowed between the marked 30 m distance in the hallway. The 
physiotherapist walked slightly behind the subject to ensure that the subject went 
his or her own pace. Every minute, the physiotherapist asked the subject for his 
or her rate of perceived exertion on the aforementioned scale.  During the walk, 
another staff member recorded all completed laps and noted heart rate, O2 Sat 
and the Borg scale number every full minute. A third staff member monitored the 
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data on a laptop that received all live data about the subject. At minute six, the 
subject stopped. Any incomplete lap was not recorded. The subject was then 
brought to a chair and the tube of the facemask was removed so the subject was 
able to breathe freely. Heart rate and O2 Sat were monitored and recorded until it 
dropped to pre-exercise values. Following the return to pre-exercise values the 
heart rate strap, pulse oximeter and metabolic vest were removed by the staff. 
Each subject also underwent two echocardiograms (Vingmed Vivid-7® 
echocardiograph, analysis using EchoPAC) which were conducted in the same 
time frame as their respective 6MWTs. The time frame ranged from six months to 
two years between tests. For the purpose of this study, only the RVSP was 
recorded. During the echo, the patient removed clothes to expose the chest. The 
subject was connected to an EKG monitor to record the electrical activity of the 
heart. The cardiologist applied gel to the patient’s chest and positioned the 
transducer on the chest to receive an image of the heart. During the test, the 
cardiologist repositioned the transducer to image different angles from the heart 
to optimize the signal from the heart chambers. After the test, the doctor wiped 
down the gel from the chest and removed the EKG electrode pads. The patient 
dressed again. 
 
Statistical Analysis 
Statistical analysis was performed using IBM SPSS Statistics 19 software 
(SPSS, Chicago, IL, USA). Descriptive statistics included demographic variables 
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(age, height, weight) (Table 3) and gas exchange variables (VE, oxygen 
consumption (VO2), carbon dioxide production (VCO2), respiratory exchange 
ratio (RER), heart rate (HR), partial pressure for end-tidal oxygen tension 
(PETO2), PETCO2, O2 Sat, VE/VCO2, 6MWT) (Table 4). We used a Pearson’s 
correlation to determine the relationship between baseline RVSP and PETCO2, 
and VE/VCO2. We also used a repeated-measures t-test to assess the change in 
RVSP, PETCO2 and VE/VCO2 between test 1 and test 2 (Table 6). In addition, we 
assessed the relationship between the change in RVSP and change in gas 
exchange parameters. An alpha level of 0.05 was used to determine statistical 
significance. Finally, we used G*Power software for a post-hoc power analysis to 
determine the sample size needed to reach significance between the change of 
VE/VCO2 and the change of RVSP. 
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CHAPTER 4. RESULTS 
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Characteristics of the patients 
Table 3 contains the demographic characteristics of all subjects. The mean age 
of the subjects was 47 ± 13 years. The height of the subjects ranged from 155 
cm to 190 cm with a mean of 168 cm. The mean weight of the subjects was 73 ± 
20 kg. The body mass index (BMI) ranged from 19 to 36 kg/m2 with a mean of 25 
kg/m2.  
 
Six-minute walk test physiology data 
Table 5 describes the physiological values of the 6MWT. The mean distance for 
the first 6MWT was 557 ± 86 m. For the second 6MWT, the mean distance was 
550 ± 126 m. Before test 1, O2 Sat had a mean of 98 ± 4 percent while the mean 
before the second 6MWT was 98 ± 1.5 percent. The lowest mean O2 Sat for test 1 
was 94 ± 4 percent and 94 ± 4.5 percent for test 2. The heart rate before the first 
6MWT averaged 76 ± 8 beats/min and 77 ± 14 beats/min for test 2. There was a 
significant difference between the maximum heart rate of test 1 (170 ±8 
beats/min) and test 2 (137 ± 25 beats/min) (p=0.04). There was a significant 
change of VCO2 post-6MWT from test 1 (0.4 ± 0.1 mL
.kg-1.min-1) to test 2 (0.95 ± 
0.24 mL.kg-1.min-1) (p=0.03). There was no significant change of VO2 post-6MWT 
between test 1 (1 ± 0.4 mL.kg-1.min-1) and test 2 (0.9 ± 0.3 mL.kg-1.min-1). VE after 
the 6MWT was 53 ± 21 l/min and 39 ± 14 l/min for test 1 and test 2, respectively. 
The respiratory exchange ratio (RER) was 1.0 ± 0.4 (test 1) and 1.0 ± 0.2 (test 
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2). The PETO2 was 116 ± 7 mmHg and 120.7 ± 8 mmHg for test 1 and test 2, 
respectively. PETCO2 was 28 ± 6 mmHg (test 1) and 29 ± 7 mmHg (test 2).  
 
Differences of PETCO2, VE/VCO2, RVSP between test 1 and test 2  
 
Table 6 shows the results of the paired-samples t-tests within PETCO2, VE/VCO2 
and RVSP for test 1 and 2. The change between PETCO2 test 1 and test 2 was 
significant (p=0.03), a decrease from a mean of 29 ± 7 mmHg to a mean of 26 ± 
6 mmHg. The difference between test 1 and test 2 of VE/VCO2 was significant 
(p<0.05) as it increased from 39 ± 9 mmHg to 44 ± 10 mmHg. There was also a 
significant difference between test 1 and test 2 for RVSP (p=0.023). For test 1, 
the mean of RVSP was 67 ± 21 mmHg and decreased to 59 ± 16 mmHg for test 
2.  
 
Correlations of PETCO2, VE/VCO2, RVSP between test 1 and 2 
As shown in Table 7, within each test, there was no significant relationship 
between the variables. There was a positive non-significant correlation (r=0.6, 
p=0.06) (Figure 1) between RVSP and VE/VCO2 in test 1 and a positive non-
significant correlation (r=0.5, p=0.33) (Figure 2) between RVSP and VE/VCO2 in 
test 2. We found a non-significant negative relationship betweenPETCO2 and 
RVSP (r=-0.6, p=0.094) (Figure 3) in test 1 and a negative correlation between 
PETCO2 and RVSP (r=-0.7, p=0.13) (Figure 4) in test 2. 
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Relationship between changes in RVSP and changes in gas exchange  
Table 8 demonstrates the relationships between the changes of RVSP and the 
changes of gas exchange. The changes of RVSP and the changes of PETCO2 
were not correlated and had no significance (r=0.2, p=0.69). The changes 
between RVSP and VE/VCO2 were non-significantly related (r=0.7, p=0.09). 
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CHAPTER 5. DISCUSSION 
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The mean of PETCO2 was 29 mmHg for test 1 and 25 mmHg for test 2 which 
shows the impact of PAH on PETCO2. The decreasing PETCO2 value between test 
1 and test 2, similar to a study by Dumitrescu et al. (2012) suggests a decline of 
pulmonary function. The PETCO2 value of a healthy person ranges from 30 - 40 
mmHg. In our study, PETCO2 further decreases during exercise while in healthy 
subjects PETCO2 increases. This opposing trend of PETCO2 in PAH patients 
demonstrates why their capacity for exercise may be limited. 
 
The mean of the VE/VCO2 slope of 39 and 44 (for test 1 and test 2, respectively) 
compared to the previously-published healthy range (Arena, 2009) of below 30 
shows the impact of PAH on VE/VCO2. This suggests that PAH patients have a 
lower output of CO2 despite increased ventilation. Since PAH patients suffer from 
the obstruction of blood vessels that impairs the blood flow in the lungs, their 
pulmonary gas exchange is drastically inhibited. Moreover, when exposed to 
exercise, the VE/VCO2 is further increased which suggests that the increased 
blood flow worsens the gas exchange in the lungs. Despite worsening of the 
ventilatory efficiency, RVSP decreased from 67 mmHg to 59 mmHg from test 1 to 
test 2. The decreased RVSP could be traced back to medication that the PAH 
patients received between the two tests, although the exact medications that 
each subject used was beyond the scope of this pilot study. The common 
medication for PAH, Isordil, is a vasodilator and thus decreases the blood 
pressure. However, as the values indicate, despite decreasing RVSP, the gas 
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exchange (PETCO2) has not improved. This opposing trend between gas 
exchange (worsens) and RVSP (improves) suggests a non-reversible, 
physiological change of the pulmonary arteries and indicates that gas exchange 
might be a more accurate measurement of disease severity than RVSP in an 
advanced state of PAH. Within each test, we did not find any relationship 
between gas exchange and RVSP; however, RVSP, VE/VCO2 and PETCO2 are 
significantly correlated when comparing each variable between the two tests. 
Moreover, when we correlated the changes of each variable to each other (Table 
8) we found a trend towards a significant relationship between the change of 
RVSP and the change of VE/VCO2 (p=0.09). These results suggest that VE/VCO2 
could be a good predictor for assessing disease severity without the need for an 
echocardiogram, however, this pilot data needs to be confirmed with a larger 
sample size.  
 
Limitations 
As this was a pilot study, we had a relatively small group of subjects with trends 
in several parameters which suggests that this study was not powered to detect 
differences in some variables that have a small effect size. Although we found a 
non-significant relationship between the changes of VE/VCO2 measured using 
6MWT and the change of RVSP (p=0.09) measured using echocardiography we 
calculated that there would likely be statistical significance (p=0.05) with an 
increased sample size (n= 16) calculated with power analysis (G*Power, 
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Duesseldorf, Germany).  In addition, we compared the 6MWD with the 
echocardiogram; however, the gold standard for assessing pulmonary 
hypertension is cardiac catheterization. Due to the invasive nature of cardiac 
catheterization, we used the echocardiogram to assess the validity of the 6MWD. 
A study by Arcasoy et al. found an overestimation of disease severity in PAH 
patients using an echocardiogram because of several reasons. First, the 
measurement of TRV tends to be inaccurate some patients (Litwin, 2010). The 
amount of the regurgitant volume must be great enough to be useful to measure 
TRV. Even with an appropriate amount of blood volume, TRV is derived through 
an estimation of PAP (Litwin, 2010) which can cause errors. However, generally 
speaking, a study by Attaran (2009) found a strong correlation (0.49; P < .001) of 
PAP estimated by echo versus right heart catheterization.  Furthermore, although 
the 6MWT is a widely used submaximal testing tool, it could be replaced with 
other submaximal tests that could be easier to conduct and standardize. A study 
by Noonan et al. (2000) implemented a different submaximal exercising protocol 
and concluded that other submaximal tests might be more sensitive, valid and 
reliable than the 6MWT (for instance, exercise tests on a treadmill could be more 
standardized). In addition, Future studies should look at 6MWD compared to right 
heart catheterization and gas exchange measurements utilizing a larger sample 
size under standard conditions in regards to treatment and timing between the 
tests. 
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CHAPTER 6. CONCLUSION 
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The purpose of the present pilot study was to determine whether the values of 
the 6MWD (PETCO2 and VE/VCO2) can be correlated to the values of the 
echocardiogram (RVSP) and thus the 6MWT could be utilized as an additional 
tool in patients with PAH, or (as necessary) possible replace the more expensive 
echocardiogram in some clinics. Our study showed that VE/VCO2 may be a good 
predictor for disease severity as it was closely related to the RVSP – an essential 
determinant for the longevity of PAH – however, our results did not reach 
statistical significance because we were underpowered (Voelkel, 2006).  
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Table 1: Functional classification of disease severity of PAH patients (Simonneau, 2009) 
  
A. New York Heart Association functional classification 
Class 1: No symptoms with ordinary physical activity. 
Class 2: Symptoms with ordinary activity. Slight limitation of activity. 
Class 3: Symptoms with less than ordinary activity. Marked limitation of 
activity. 
Class 4: Symptoms with any activity or even at rest. 
B. World Health Organization functional assessment classification 
Class I: Patients with PH but without resulting limitation of physical activity. 
Ordinary physical activity does not cause undue dyspnea or 
fatigue, chest pain, or near syncope. 
Class II: Patients with PH resulting in slight limitation of physical activity. 
They are comfortable at rest. Ordinary physical activity causes 
undue dyspnea or fatigue, chest pain, or near syncope. 
Class III: Patients with PH resulting in marked limitation of physical activity. 
They are comfortable at rest. Less than ordinary activity causes 
undue dyspnea or fatigue, chest pain, or near syncope. 
Class IV: Patients with PH with inability to carry out any physical activity 
without symptoms. These patients manifest signs of right-heart 
failure. Dyspnea and/or fatigue may even be present at rest. 
Discomfort is increased by any physical activity. 
Table reprinted with permission from Rubin LJ. Diagnosis and 
management of pulmonary arterial hypertension: ACCP Evidence-Based 
Clinical Practice Guidelines. Introduction. Chest. 2004; 126:7S-10S. 
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Table 2: Comparison of VE/VCO2 and PETCO2 in healthy and PAH subjects (Arena, 2009)  
  Healthy  PAH   
VE/VCO2 Rest <30s 30s-60s   
  Post-exercise <30s 30s-60s   
PETCO2 (mmHg) Rest High 30s-low 40s low 20s-low 30s   
  Post-exercise 3-8 mmHg increase low 30s – 18   
PETCO2- partial pressure of end-tidal carbon dioxide 2 - VE/VCO2-Ventilatory equivalent ratio for carbon dioxide 
 
 
* In healthy subjects PETCO2 increases with exercise. However, in PAH patients it flattens or even decreases which is 
conversely related to disease severity. 
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Table 3: Borg Scale 
 
 
 
Source: http://www.vavaveteran.co.uk/wp-content/uploads/2013/04/RPE.jpg 
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Table 4: Demographics of subjects 
 
 
 
    
  
  Mean   SD Range 
Age (years) 47.89 ± 12.7 26 - 66 
Height (cm) 168.88 ± 11.6 155 - 190 
Weight (kg) 72.75 ± 20.2 48 - 109 
Body Mass Index (BMI) (kg/m2) 25.22 ± 5.18 18.7 - 35.6 
   39 
  Table 5: Six-minute walk test physiology data  
 
N Test1 Test 2 Difference p 
6MWD (m) 10 557 ± 86 550 ± 126 -57 0.89 
O2 Sat pre*
1 (%) 10 98 +4 98 ± 1.5 0 1 
O2 Sat min (%) 10 94 ± 4 94 ±4.5 0 1 
HR pre (beats/min) 10 76 ± 8 77 ± 14 1 0.89 
HR max (beats/min) 10 170 ± 8 137 ± 25 -33 0.04* 
VO2 post*
2 (mL . kg-1 . min-1) 8 1± 0.4 0.9 ± 0.3 -0.1 0.66 
VCO2 post (mL . kg-1 . min-1) 8 0.4± 0.1 0.9 ± 0.24 0.55 0.03* 
VE post (l/min) 8 53 ± 21 39 ± 14 -14 0.26 
RER 8 1 ± 0.4 1 ± 0.2 0 1 
PETO2 (mmHg) 8 116 ± 7 121 ± 8 4 0.13 
PETCO2 (mmHg) 8 29 ± 7 26 ± 6 -3 0.03* 
 
  
 
 
 
 
  
HR- heart rate 6MWD- Distance walked during 6-minute walk test  
O2 Sat- saturation level of oxygen in hemoglobin  
RER-respiratory exchange ratio, VO2 – oxygen consumption rate, VCO2 – 
carbon dioxide consumption rate, VE- minute ventilation, PETO2- partial 
pressure of expiratory oxygen, PETCO2 – partial pressure of end-tidal CO2, *1 
pre- before test, *2 post-test, * significant 
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Table 6: Differences of gas exchange and RVSP for test 1 and 2 
 
 
 
  
 
Test 1 Test 2 p 
PETCO2 (mmHg) 29 ± 7 26 ± 6 0.03* 
RVSP (mmHg) 67 ± 21 59 ± 16 0.02* 
VE/VCO2 slope 39 ± 9 44 ± 10 0.05* 
VE/VCO2-Ventilatory equivalent ratio for carbon dioxide 
RVSP-Right ventricular systolic pressure 
PETCO2- partial pressure of end-tidal carbon dioxide 
* 0.05 significant 
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Table 7: Correlations of PETCO2, VE/VCO2, RVSP between test 1 and 2 
 
 
 
 
 
 
 
         
  
 
RVSP (mmHg) 
 
Test 1 Test 2 
 
p r p r 
PETCO2 (mmHg) 0.094 -0.557 0.13 -0.689 
VE/VCO2 slope 0.06 0.612 0.33 0.485 
PETCO2- partial pressure of end-tidal carbon dioxide  
VE/VCO2-Ventilatory equivalent ratio for carbon dioxide  
RVSP-Right ventricular systolic pressure  
* 0.05 significant 
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Table 8: Change between PETCO2, VE/VCO2 and RVSP for test 1 and 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  RVSP (mmHg) 
  Δ Test 1-2 
  p r 
PETCO2 
(mmHg) 
0.699 0.18 
VE/VCO2 slope 0.09 0.69 
VE/VCO2-Ventilatory equivalent ratio for carbon dioxide 
RVSP-Right ventricular systolic pressure 
PETCO2- partial pressure of end-tidal carbon dioxide 
* 0.05 significant 
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Figure 1: Correlation between RVSP and VE/VCO2 for test 1 (r=0.6, p=0.06) 
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Figure 2: Correlation between RVSP and VE/VCO2 for test 2 (r=0.5, p=0.33) 
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Figure 3: Correlation between RVSP and PETCO2 for test 1 (r=0.6, p=0.06)  
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Figure 4: Correlation between RVSP and PETCO2 for test 2 (r=0.7, p=0.13) 
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